Update in hematology: Heparin-induced thrombocytopenia and bivalirudin

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 25, Issue 2, 2011, Pages 371-375

  Augoustides, John G T ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

antibodies; bivalirudin; cardiac surgery; direct thrombin inhibitor; heparin; heparin induced thrombocytopenia; lepirudin; low molecular weight heparin; percutaneous coronary intervention; platelet blockade; thrombocytopenia; thrombosis; warfarin

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ANTITHROMBOCYTIC AGENT; APROTININ; ARGATROBAN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARIN LYASE; HEPARIN PLATELET FACTOR 4 ANTIBODY; HIRULOG; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEPIRUDIN; PROSTACYCLIN; PROTAMINE; PROTEIN C; TIROFIBAN; VITAMIN K GROUP; WARFARIN;

ABSENCE OF SIDE EFFECTS; ADVERSE OUTCOME; ANTICOAGULANT THERAPY; BLOOD CLOTTING TIME; CARDIAC PATIENT; CARDIOPULMONARY BYPASS; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CREATININE CLEARANCE; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG USE; GANGRENE; GOLD STANDARD; HEART SURGERY; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LENGTH OF STAY; LIMB DISEASE; LUNG EMBOLISM; MORTALITY; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEROCONVERSION; SUBSTITUTION THERAPY; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM; THROMBOSIS; TREATMENT PLANNING; VENOUS THROMBOEMBOLISM;

ANIMALS; CARDIAC SURGICAL PROCEDURES; HEMATOLOGY; HEPARIN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 79954421444     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2010.12.015     Document Type: Review

References (42)

1. Spencer FA: Heparin-induced thrombocytopenia: patient profiles and clinical manifestations. J Thromb Thrombolysis 10:S21-S26, 2000
2. Wallenga JM, Jeske WP, Messmore HL: Mechanisms of venous and arterial thrombosis in heparin induced thrombocytopenia. J Thromb Thrombolysis 10:S13-S20, 2000 (Pubitemid 32093940)
3. Ohman EM, Granger CB, Rice L, et al: Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: A registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. J Thromb Thrombolysis 10:11-19, 2005 (Pubitemid 40959209)
4. Crespo EM, Oliveira GBF, Honeycut EF, et al: Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications after Thrombocytopenia Caused by heparin (CATCH) registry. Am Heart J 157:651-657, 2009
5. Ban-Hoefen M, Francis C: Heparin-induced thrombocytopenia and thrombosis in a tertiary care hospital. Thromb Res 124:189-192, 2009
6. Thielmann M, Bunschkowski M, Tossios P, et al: Perioperative thrombocytopenia in cardiac surgical patients - Incidence of heparin-induced thrombocytopenia, morbidities and mortality. Eur J Cardiothorac Surg 37:1391-1395, 2010
7. Selleng S, Malowsky, Strobel U, et al: Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemaost 8:30-36, 2010
8. Kuitunen A, Suojaranta-Ylinen R, Raivio P, et al: Heparin-induced thrombocytopenia following cardiac surgery is associated with poor outcome. J Cardiothorac Vasc Anesth 21:18-22, 2007 (Pubitemid 46199243)
9. Kerendi F, Thourani VH, Puskas JD, et al: Impact of heparin-induced thrombocytopenia on postoperative outcomes after cardiac surgery? Ann Thorac Surg 84:1548-1553, 2007
10. Assman A, Boeken IJ, Feindl P, et al: Heparin-induced thrombocytopenia type II after cardiac surgery: predictors and outcome. Thorac Cardiovasc Surg 58:463-467, 2010
11. Levy JH, Tanaka KA, Hursting MJ, et al: Reducing thrombotic complications in the perioperative setting: an update on heparin-induced thrombocytopenia. Anesth Analg 105:570-582, 2007 (Pubitemid 47300828)
12. Everett BM, Yeh R, Foo SY, et al: Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg 83:592-597, 2007 (Pubitemid 46135456)
13. Mullen MP, Wessel DL, Thomas KC, et al: The incidence and implications of anti-heparin-platelet factor 4 antibody formation in a pediatric cardiac surgical population. Anesth Analg 107:371-378, 2008
14. Greinacher A, Levy JH: HIT happens: Diagnosing and evaluating the patient with heparin-induced thrombocytopenia. Anesth Analg 107:356-358, 2008
15. Selleng S, Malowsky B, Itterman T, et al: Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery. Am Heart J 160:362-369, 2010
16. Warkentin TE, Greinacher A, Koster A, et al: Treatment and prevention of heparin-induced thrombocytopenia. Chest 133:340S-380S, 2008
17. Levy JH, Winkler AM: Heparin-induced thrombocytopenia and cardiac surgery. Curr Opin Anaesthesiol 23:74-79, 2010
18. Greinacher A: Heparin-induced thrombocytopenia. J Thromb Haemost 7:9-12, 2009
19. Warkentin TE, Elavathil LJ, Hayward CPM, et al: The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytoipenia. Ann Intern Med 127:804-812, 1997 (Pubitemid 27465548)
20. Srinivasan AF, Rice L. Bartholomew JR, et al: Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 164:66-70, 2004 (Pubitemid 38067390)
21. Warkentin TE, Roberts RS, Hirsh J, et al: Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: A nested cohort study. Chest 127:1857-1861, 2005
22. Warkentin TE: Should vitamin K be administered when HIT is diagnosed after administration of coumarin? J Thromb Haemost 4:894-896, 2006
23. Murphy GS, Marymont JH: Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery. J Cardiothorac Vasc Anesth 21:113-126, 2007 (Pubitemid 46199247)
24. Warkentin TE, Kelton JG: Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344:1286-1292, 2001 (Pubitemid 32372963)
25. Lubenow N, Kempf R, Eichner A, et al: Heparin-induced thrombocytopenia: Temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 122:37-42, 2002 (Pubitemid 34754140)
26. Otis SA, Zehnder JL: Heparin-induced thrombocytopenia: Current status and diagnostic challenges. Am J Hematol 85:700-706, 2010
27. Smedira NG, Dyke CM, Koster A, et al: Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: The results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 131:686-692, 2006
28. Koster A, Spiess B, Jurmann M, et al: Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: Results of the "EVOLUTION OFF" trial. Anesth Analg 103:540-544, 2006
29. Dyke CM, Smedira NG, Koster A, et al: A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON study. J Thorac Cardiovasc Surg 131:533-539, 2006
30. Koster A, Dyke CM, Aldea G, et al: Bivalirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and heparin antibodies: The CHOOSE-ON trial. Ann Thorac Surg 83:572-577, 2007 (Pubitemid 46156924)
31. Dyke CM, Aldea G, Koster A, et al: Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor 4/heparin antibodies. Ann Thorac Surg 84:836-839, 2007 (Pubitemid 47285016)
32. Van De Car DA, Rao SV, Ohman EM: Bivalirudin: A review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther 8:1673-1681, 2010
33. Anand SX, Villes-Gonzalez JF, Mahboobi SK, et al: Bivalirudin utilization in cardiac surgery: Shifting anticoagulation from indirect to direct thrombin inhibition. Can J Anaesth 2010 [Epub ahead of print]
34. Stafford-Smith M, Lefrak EA, Qazi AG, et al: Efficacy and safety of heparinase-1 versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology 103:229-240, 2005 (Pubitemid 41076719)
35. Bittl JA, Strony J, Brinker JA, et al: Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 333:764-769, 1995
36. Rao SV, Ohman EM: Anticoagulant therapy for percutaneous coronary intervention. Circ Cardiovasc Interv 3:80-88, 2010
37. Lindsey JB, Cohen DJ, Stolker JM, et al: The impact of bivalirudin on percutaneous coronary intervention-related bleeding. Eurointervention 6:206-213, 2010
38. Lobato RL, Despotis GJ, Levy JH, et al: Anticoagulation management during cardiopulmonary bypass: A survey of 54 North American institutions. J Thorac Cardiovasc Surg 139:1665-1666, 2010
39. Levy JH, Dutton RP, Hemphill JC, et al: Multidisciplinary approach to the challenge of hemostasis. Anesth Analg 110:354-354, 2010
40. Augoustides JG: Aprotinin and renal dysfunction: What does history teach us? Expert Opin Drug Saf 8:5-7, 2009
41. Augoustides JG: Perioperative safety of aprotinin in coronary artery bypass graft surgery: Is there life after BART? Drug Saf 31:557-560, 2008
42. Fergusson DA, Hebert PC, Mazer CD, et al: A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358:2319-2331, 2008 (Pubitemid 351749156)